Huang Ge, Liu Guo, Zhou Zhiguo, Yang Jinfeng, Su Chen
Department of Anesthesiology and Pain Medicine, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, 410013, China.
University of South China, Hengyang, 421001, Hunan, China.
Pain Ther. 2020 Dec;9(2):797-804. doi: 10.1007/s40122-020-00183-3. Epub 2020 Jul 12.
Patients who have refractory cancer pain suffer both physically and psychologically. Cancer pain management has improved over the past few decades. However, the treatment of refractory cancer pain is still challenging all over the world. Intraspinal analgesia has become an effective strategy to treat refractory pain in patients with cancer. In this report, we present a patient receiving a large dose of intrathecal opioids for refractory cancer pain, and who is also afflicted with pain-induced depression. Dexmedetomidine (DEX) was used as part of a multimodal analgesic regimen that successfully alleviated both the patient's pain and depression. An intrathecal infusion of DEX may serve as an adjuvant drug in the treatment of cancer pain and pain-related depression.
患有难治性癌痛的患者在身体和心理上都备受折磨。在过去几十年里，癌症疼痛管理已有改善。然而，难治性癌痛的治疗在全球范围内仍然具有挑战性。鞘内镇痛已成为治疗癌症患者难治性疼痛的有效策略。在本报告中，我们介绍了一名接受大剂量鞘内阿片类药物治疗难治性癌痛且同时患有疼痛诱导性抑郁症的患者。右美托咪定（DEX）作为多模式镇痛方案的一部分使用，成功缓解了患者的疼痛和抑郁。鞘内输注DEX可作为治疗癌痛及疼痛相关抑郁症的辅助药物。
